XTAE
BLRX
Market cap383mUSD
Oct 07, Last price
1.20ILS
1D
0.00%
1Q
-20.00%
Jan 2017
-99.65%
IPO
-99.98%
Name
BioLine RX Ltd
Chart & performance
P/E
—
P/S
8.63
EPS
—
Div yield, %
—
Shrs. gr., 5y
-24.60%
Rev. gr., 5y
%
Revenues
1m
-95.89%
Net income
-1m
L-87.16%
CFO
-8m
L-81.45%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Key people
Philip Serlin
Chief Executive Officer · since 2016
Mali Zeevi
Chief Financial Officer · since 2016
Ella Sorani
Vice President - Development · since 2017
Abi Vainstein-Haras
Vice President-Clinical & Medical Affairs · since 2017
Hillit Mannor Shachar
Vice President - Business Development · since 2018
Director · since 2010
Barbara-Jean Bormann
Director · since 2013
Raphael Hofstein
Director · since 2003
Director · since 2014
Chairman of the Board · since 2003
External Director · since 2010
Avraham Molcho
External Director · since 2010
Gal Cohen
Independent Director · since 2023
Headquarters & legal address
Modi'in Technology Park, 2 HaMa'ayan Street
Modi'in, TA 7177871
IL
Modi'in, TA 7177871
IL
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||